Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 23 of 23

List	Outcome	Time frame	Description
Secondary	Pharmacokinetics (PK) profile of REGN2477	Up to Week 30	Assessed via serum concentration of REGN2477 over time
Secondary	Pharmacokinetics (PK) profile of REGN1033	Up to Week 30	Assessed via serum concentration of REGN1033 over time
Secondary	Immunogenicity of REGN2477+REGN1033	Up to Week 30	As determined by the presence or absence of anti-drug antibodies (ADA)

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03710941/registered?page=2